{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:09:11Z","timestamp":1790363351885,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T00:00:00Z","timestamp":1574640000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s11912-019-0852-9","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T20:02:30Z","timestamp":1574712150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era"],"prefix":"10.1007","volume":"21","author":[{"given":"Alex","family":"Friedlaender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Buffoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Addeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,25]]},"reference":[{"key":"852_CR1","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.jtho.2016.05.021","volume":"11","author":"TY Cheng","year":"2016","unstructured":"Cheng TY, Cramb SM, Baade PD, et al. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol : official publication of the International Association for the Study of Lung Cancer. 2016;11:1653\u201371.","journal-title":"J Thorac Oncol : official publication of the International Association for the Study of Lung Cancer"},{"key":"852_CR2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3389\/fonc.2019.00264","volume":"9","author":"A Addeo","year":"2019","unstructured":"Addeo A, Banna GL, Metro G, Di Maio M. Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review and literature-based meta-analysis. Front Oncol. 2019;9:264.","journal-title":"Front Oncol"},{"key":"852_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.cllc.2014.07.002","volume":"15","author":"L Landi","year":"2014","unstructured":"Landi L, Tiseo M, Chiari R, et al. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors. Clin Lung Cancer. 2014;15:411\u20137 e414.","journal-title":"Clin Lung Cancer"},{"key":"852_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.critrevonc.2018.06.016","volume":"129","author":"Giuseppe Luigi Banna","year":"2018","unstructured":"\u2022\u2022 Banna GL, Passiglia F, Colonese F, et al. Immune-checkpoint inhibitors in non-small cell lung cancer: a tool to improve patients\u2019 selection. Crit Rev Oncol Hematol. 2018;129:27\u201339. Important tool to better select patients to Immune checkpoint inhibitors.","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"852_CR5","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/annonc\/mdw326","volume":"27","author":"S Novello","year":"2016","unstructured":"Novello S, Barlesi F, Califano R, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol : official journal of the European Society for Medical Oncology. 2016;27:v1\u2013v27.","journal-title":"Ann Oncol : official journal of the European Society for Medical Oncology"},{"key":"852_CR6","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1200\/JCO.2017.74.6065","volume":"35","author":"N Hanna","year":"2017","unstructured":"Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol : official journal of the American Society of Clinical Oncology. 2017;35:3484\u2013515.","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"key":"852_CR7","unstructured":"\u2022 Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compre Cancer Netw : JNCCN. 2017;15:504\u201335. Guidelines showing the lack of strong data about activity in patients with NSCLC and performance status."},{"key":"852_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/JTO.0b013e3181622c17","volume":"3","author":"RC Lilenbaum","year":"2008","unstructured":"Lilenbaum RC, Cashy J, Hensing TA, et al. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol : official publication of the International Association for the Study of Lung Cancer. 2008;3:125\u20139.","journal-title":"J Thorac Oncol : official publication of the International Association for the Study of Lung Cancer"},{"key":"852_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"852_CR10","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.6004\/jnccn.2014.0098","volume":"12","author":"A Gajra","year":"2014","unstructured":"Gajra A, Marr AS, Ganti AK. Management of patients with lung cancer and poor performance status. J Natl Compre Cancer Netw : JNCCN. 2014;12:1015\u201325.","journal-title":"J Natl Compre Cancer Netw : JNCCN"},{"key":"852_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ejca.2017.07.002","volume":"83","author":"C Su","year":"2017","unstructured":"Su C, Zhou F, Shen J, et al. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced non-small cell lung cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - still a daily challenge. Eur J Cancer. 2017;83:266\u201378.","journal-title":"Eur J Cancer"},{"key":"852_CR12","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1200\/JCO.18.02118","volume":"37","author":"A Passaro","year":"2019","unstructured":"Passaro A, Spitaleri G, Gyawali B, de Marinis F. Immunotherapy in non-small-cell lung cancer patients with performance status 2: clinical decision making with scant evidence. J Clin Oncol : official journal of the American Society of Clinical Oncology. 2019;37:1863\u20137.","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"key":"852_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3322\/caac.21406","volume":"67","author":"CG Ethun","year":"2017","unstructured":"Ethun CG, Bilen MA, Jani AB, et al. Frailty and cancer: implications for oncology surgery, medical oncology, and radiation oncology. CA Cancer J Clin. 2017;67:362\u201377.","journal-title":"CA Cancer J Clin"},{"key":"852_CR14","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jamda.2013.03.022","volume":"14","author":"JE Morley","year":"2013","unstructured":"Morley JE, Vellas B, van Kan GA, et al. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14:392\u20137.","journal-title":"J Am Med Dir Assoc"},{"key":"852_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/BF02982161","volume":"12","author":"G Abellan van Kan","year":"2008","unstructured":"Abellan van Kan G, Rolland Y, Bergman H, et al. The I.A.N.A Task Force on frailty assessment of older people in clinical practice. J Nutr Health Aging. 2008;12:29\u201337.","journal-title":"J Nutr Health Aging"},{"key":"852_CR16","unstructured":"\u2022 Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241\u201352. Stregthening the importnace and the role of CGA as an assesment tool in the geriatric population."},{"key":"852_CR17","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s00277-013-2001-0","volume":"93","author":"ME Hamaker","year":"2014","unstructured":"Hamaker ME, Mitrovic M, Stauder R. The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy. Ann Hematol. 2014;93:1031\u201340.","journal-title":"Ann Hematol"},{"key":"852_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115060","volume":"9","author":"P Soubeyran","year":"2014","unstructured":"Soubeyran P, Bellera C, Goyard J, et al. Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. PLoS One. 2014;9:e115060.","journal-title":"PLoS One"},{"key":"852_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.2013.51.1345","volume":"32","author":"C Kenis","year":"2014","unstructured":"Kenis C, Decoster L, Van Puyvelde K, et al. Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol : official journal of the American Society of Clinical Oncology. 2014;32:19\u201326.","journal-title":"J Clin Oncol : official journal of the American Society of Clinical Oncology"},{"key":"852_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210499","volume":"14","author":"Y Agemi","year":"2019","unstructured":"Agemi Y, Shimokawa T, Sasaki J, et al. Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: a single-institution study. PLoS One. 2019;14:e0210499.","journal-title":"PLoS One"},{"key":"852_CR21","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.cllc.2017.02.006","volume":"18","author":"KJG Schulkes","year":"2017","unstructured":"Schulkes KJG, Souwer ETD, van Elden LJR, et al. Prognostic value of geriatric 8 and identification of seniors at risk for hospitalized patients screening tools for patients with lung cancer. Clin Lung Cancer. 2017;18:660\u20136 e661.","journal-title":"Clin Lung Cancer"},{"issue":"5","key":"852_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"Mary E. Charlson","year":"1987","unstructured":"\u2022\u2022 Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373\u201383. This is the milestone for the development of an the tool to assess comorbidities.","journal-title":"Journal of Chronic Diseases"},{"key":"852_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2147\/CLEP.S133624","volume":"9","author":"K Stavem","year":"2017","unstructured":"Stavem K, Hoel H, Skjaker SA, Haagensen R. Charlson comorbidity index derived from chart review or administrative data: agreement and prediction of mortality in intensive care patients. Clin Epidemiol. 2017;9:311\u201320.","journal-title":"Clin Epidemiol"},{"key":"852_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12890-017-0452-0","volume":"17","author":"L Zhao","year":"2017","unstructured":"Zhao L, Leung LH, Wang J, et al. Association between Charlson comorbidity index score and outcome in patients with stage IIIB-IV non-small cell lung cancer. BMC Pulm Med. 2017;17:112.","journal-title":"BMC Pulm Med"},{"key":"852_CR25","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245\u201351.","journal-title":"J Clin Epidemiol"},{"key":"852_CR26","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/jgs.15750","volume":"67","author":"E Muchnik","year":"2019","unstructured":"Muchnik E, Loh KP, Strawderman M, et al. Immune checkpoint inhibitors in real-world treatment of older adults with non-small cell lung Cancer. J Am Geriatr Soc. 2019;67:905\u201312.","journal-title":"J Am Geriatr Soc"},{"key":"852_CR27","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol: official journal of the European Society for Medical Oncology. 2018;29:iv192\u2013237.","journal-title":"Ann Oncol: official journal of the European Society for Medical Oncology"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-019-0852-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-019-0852-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-019-0852-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,24]],"date-time":"2020-11-24T00:29:44Z","timestamp":1606177784000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-019-0852-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1007\/s11912-019-0852-9","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"25 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Alex Friedlaender has received compensation from Roche, Pfizer, Astellas and Bristol-Myers Squibb for service as a consultant.Giuseppe Luigi Banna has received compensation from Merck Sharpe & Dohme, Boehringer Ingelheim, Janssen-Cilag and Roche for participating on advisory boards.Lucio Buffoni has received compensation from Pfizer, Bristol-Myers Squibb, Merck Sharpe & Dohme, AstraZeneca and Boehringer Ingelheim for participating on advisory boards.Alfredo Addeo has received research funding from Boehringer Ingelheim, and has received compensation from Bristol-Myers Squibb, AstraZeneca, Merck Sharpe & Dohme, Takeda, Pfizer, Roche and Boehringer Ingelheim for participating on advisory boards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"107"}}